EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Comparative neurologic toxicity profiles of chemotherapy versus immune checkpoint inhibitors in melanoma: a propensity score-matched analysis

Majd A Abualrob, Sami Alshehab, Yousef Awad, Ranim Toma, Tarneem Azzam, Rand Abdellatif, Ali Al-Salahat, Shahd Hamid

Supportive Care in Cancer · 2026-06 · 34 (6)

DOI: 10.1007/s00520-026-10745-4 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Supportive Care in Cancer, online erschienen am 14.05.2026. Verfasst von Majd A Abualrob und 7 weiteren Autor:innen. Beteiligte Einrichtung: Neuroscience Institute, Hamad General Hospital, Doha, Qatar. majdaiabualrob72@gmail.com. Hauptthemen laut MEDLINE: Melanoma, Immune Checkpoint Inhibitors, Neurotoxicity Syndromes, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hamad Medical Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Immune checkpoint inhibitors (ICIs) have transformed melanoma treatment, yet comparative real-world data characterizing ICI-associated neurologic adverse events against the well-established neurotoxicity profile of conventional chemotherapy remain limited. We sought to contextualize the neurologic risk landscape of ICIs relative to chemotherapy as a historical comparator, to inform treatment-specific supportive care and surveillance strategies.

Methods

We performed a propensity score–matched analysis using the TriNetX Global Collaborative Network, encompassing 162 healthcare organizations. Adult patients with melanoma receiving chemotherapy (dacarbazine, paclitaxel, carboplatin, or temozolomide; n = 9787) or ICI therapy (pembrolizumab, nivolumab, or ipilimumab; n = 14,627) from January 2014 through November 2025 were identified. After 1:1 nearest-neighbor matching on 52 baseline covariates, 6887 pairs were analyzed over 1–1095 days post-index therapy. Primary outcomes were peripheral neuropathy, encephalopathy, and laboratory-anchored myositis (ICD-10 myositis codes with creatine kinase ≥ 500 U/L). Fractures served as a negative control. A pre-specified conservative sensitivity analysis excluded bidirectional treatment switching, restricted the ICI cohort to anti-PD-1 predominant exposure, tightened outcome definitions, and extended follow-up to 5 years.

Results

Among 13,774 matched patients (mean age 67.1 years; 48.5% male), peripheral neuropathy occurred in 7.2% of chemotherapy-treated versus 3.2% of ICI-treated patients (HR 2.47; 95% CI 2.10–2.92). Encephalopathy occurred in 1.0% versus 1.4% (HR 0.70; 95% CI 0.51–0.96). Laboratory-confirmed myositis occurred in 1.0% versus 2.1% (HR 0.47; 95% CI 0.35–0.64). No cases of Guillain–Barré syndrome or CNS vasculitis were detected. The negative control showed no significant difference ( P = .20). In the conservative sensitivity analysis (6640 matched pairs; 5-year follow-up), the peripheral neuropathy association was substantially strengthened (HR 5.45; 95% CI 4.16–7.15) and the laboratory-anchored myositis association was essentially unchanged (HR 0.46; 95% CI 0.33–0.64), while the encephalopathy association attenuated to null (HR 1.03; 95% CI 0.79–1.34).

Conclusions

Chemotherapy carries a substantially higher peripheral neuropathy risk, while ICI therapy confers elevated laboratory-confirmed myositis risk. These robust findings support treatment-specific neurologic surveillance and supportive care strategies in melanoma management, particularly neuropathy monitoring during chemotherapy and neuromuscular/CK surveillance during ICI therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaImmune Checkpoint InhibitorsNeurotoxicity SyndromesAntineoplastic AgentsHumansMaleFemalePropensity ScoreAgedMiddle AgedPeripheral Nervous System DiseasesRetrospective StudiesAdult

Stichwörter der Autor:innen

Chemotherapy-induced peripheral neuropathyImmune checkpoint inhibitorsImmune-related adverse eventsMelanomaMyositisReal-world evidenceSupportive cancer care

Substanzen

Immune Checkpoint InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • Neuroscience Institute, Hamad General Hospital, Doha, Qatar. majdaiabualrob72@gmail.com.
  • Neuroscience Institute, Hamad General Hospital, Doha, Qatar.
  • Internal Medicine, Hamad General Hospital, Doha, Qatar.
  • Arab American University, Jenin, Palestine.
  • Palestinian Ministry of Health, Ramallah, Palestine.
  • Neurology Department, Creighton University, Omaha, NE, USA.

Förderung

  • Hamad Medical Corporation

Zitieren

APA

Abualrob, M. A., Alshehab, S., Awad, Y., Toma, R., Azzam, T., Abdellatif, R., Al-Salahat, A., & Hamid, S. (2026). Comparative neurologic toxicity profiles of chemotherapy versus immune checkpoint inhibitors in melanoma: a propensity score-matched analysis. Supportive Care in Cancer, 34(6). https://doi.org/10.1007/s00520-026-10745-4

Vancouver

Abualrob MA, Alshehab S, Awad Y, Toma R, Azzam T, Abdellatif R, et al. Comparative neurologic toxicity profiles of chemotherapy versus immune checkpoint inhibitors in melanoma: a propensity score-matched analysis. Supportive Care in Cancer. 2026;34(6). doi:10.1007/s00520-026-10745-4

BibTeX
@article{Abualrob2026,
  author = {Abualrob, Majd A and Alshehab, Sami and Awad, Yousef and Toma, Ranim and Azzam, Tarneem and Abdellatif, Rand and Al-Salahat, Ali and Hamid, Shahd},
  title = {Comparative neurologic toxicity profiles of chemotherapy versus immune checkpoint inhibitors in melanoma: a propensity score-matched analysis},
  journal = {Supportive Care in Cancer},
  year = {2026},
  volume = {34},
  number = {6},
  doi = {10.1007/s00520-026-10745-4}
}
Kostenlos starten →